Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study
暂无分享,去创建一个
Alan S. Perelson | Laetitia Canini | Jessica M. Conway | Fabrice Carrat | A. Perelson | F. Carrat | J. Conway | L. Canini
[1] R. Webster,et al. Competitive Fitness of Oseltamivir-Sensitive and -Resistant Highly Pathogenic H5N1 Influenza Viruses in a Ferret Model , 2010, Journal of Virology.
[2] A. Monto,et al. The role of antivirals in the control of influenza. , 2003, Vaccine.
[3] Andreas Handel,et al. Towards a quantitative understanding of the within-host dynamics of influenza A infections , 2010, Journal of The Royal Society Interface.
[4] D M Fleming,et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. , 1997, The New England journal of medicine.
[5] Arjun Srinivasan,et al. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients--North Carolina, 2009. , 2011, The Journal of infectious diseases.
[6] P. Ward,et al. Oral oseltamivir treatment of influenza in children , 2001, The Pediatric infectious disease journal.
[7] A. Perelson,et al. Kinetics of Influenza A Virus Infection in Humans , 2006, Journal of Virology.
[8] S. Trottier,et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial , 2000, The Lancet.
[9] Daniel Coombs,et al. Stochastic Analysis of Pre- and Postexposure Prophylaxis against HIV Infection , 2013, SIAM J. Appl. Math..
[10] Jo Leonardi-Bee,et al. Impact of Neuraminidase Inhibitor Treatment on Outcomes of Public Health Importance During the 2009–2010 Influenza A(H1N1) Pandemic: A Systematic Review and Meta-Analysis in Hospitalized Patients , 2012, The Journal of infectious diseases.
[11] Nicholas C. Wu,et al. Systematic Identification of H274Y Compensatory Mutations in Influenza A Virus Neuraminidase by High-Throughput Screening , 2012, Journal of Virology.
[12] Larisa V. Gubareva,et al. Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants , 2001, Antimicrobial Agents and Chemotherapy.
[13] S. Gorman,et al. Stockpiling Antiviral Drugs for the Next Influenza Pandemic , 2009, Clinical pharmacology and therapeutics.
[14] Ronald Gieschke,et al. Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid , 2008, Journal of clinical pharmacology.
[15] G. Bocharov,et al. Mathematical model of antiviral immune response. III. Influenza A virus infection. , 1994, Journal of theoretical biology.
[16] N. J. White,et al. Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers , 2008, Antimicrobial Agents and Chemotherapy.
[17] Paulette Clancy,et al. A "partitioned leaping" approach for multiscale modeling of chemical reaction dynamics. , 2006, The Journal of chemical physics.
[18] Benjamin J Cowling,et al. Heterogeneity in viral shedding among individuals with medically attended influenza A virus infection. , 2013, The Journal of infectious diseases.
[19] P. Ward,et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. , 1999, JAMA.
[20] A. Monto,et al. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] Andreas Handel,et al. Neuraminidase Inhibitor Resistance in Influenza: Assessing the Danger of Its Generation and Spread , 2007, PLoS Comput. Biol..
[22] F Y Aoki,et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. , 2000, Lancet.
[23] Guy Boivin,et al. Role of Permissive Neuraminidase Mutations in Influenza A/Brisbane/59/2007-like (H1N1) Viruses , 2011, PLoS pathogens.
[24] John Samuel,et al. A simple cellular automaton model for influenza A viral infections. , 2004, Journal of theoretical biology.
[25] Draft WHO guidelines on the use of vaccines and antivirals during influenza pandemics. , 2002, Releve epidemiologique hebdomadaire.
[26] A. Perelson,et al. Simulation and Prediction of the Adaptive Immune Response to Influenza A Virus Infection , 2009, Journal of Virology.
[27] Christian Stock,et al. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. , 2009, The Lancet. Infectious diseases.
[28] Update on oseltamivir-resistant pandemic A (H1N1) 2009 influenza virus: January 2010. , 2009, Releve epidemiologique hebdomadaire.
[29] Maria Theodoridou,et al. Safety and Pharmacokinetics of Oseltamivir for Prophylaxis of Neonates Exposed to Influenza H1N1 , 2012, The Pediatric infectious disease journal.
[30] Leming,et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections , 1997 .
[31] Laurent Kaiser,et al. Influenza virus neuraminidase inhibitors , 2000, The Lancet.
[32] Alan S. Perelson,et al. Quantifying the Early Immune Response and Adaptive Immune Response Kinetics in Mice Infected with Influenza A Virus , 2010, Journal of Virology.
[33] Benjamin J Cowling,et al. Comparative epidemiology of pandemic and seasonal influenza A in households. , 2010, The New England journal of medicine.
[34] Laetitia Canini,et al. Population Modeling of Influenza A/H1N1 Virus Kinetics and Symptom Dynamics , 2010, Journal of Virology.
[35] F. Hayden,et al. Perspectives on antiviral use during pandemic influenza. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[36] H. C. Cousland. Learning by objectives. , 1972, Radiography.
[37] Yoshihiro Kawaoka,et al. oseltamivir: descriptive study , 2022 .
[38] M. Ison,et al. Optimum timing of oseltamivir: lessons from Bangladesh. , 2014, The Lancet. Infectious diseases.
[39] Phillip Andrew Reece,et al. Neuraminidase inhibitor resistance in influenza viruses , 2007, Journal of medical virology.
[40] Alan S. Perelson,et al. Stochastic Theory of Early Viral Infection: Continuous versus Burst Production of Virions , 2011, PLoS Comput. Biol..
[41] F. Hayden,et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. , 2001, The Journal of infectious diseases.
[42] Gilles Clermont,et al. A Dynamical Model of Human Immune Response to Influenza a Virus Infection , 2006 .
[43] Sebastian Maurer-Stroh,et al. Antigenic Drift of the Pandemic 2009 A(H1N1) Influenza Virus in a Ferret Model , 2013, PLoS pathogens.
[44] Peter Doshi,et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults , 2010 .
[45] Yacine Abed,et al. Chantal Mice and in Ferrets , in In Vitro Influenza A ( H 1 N 1 ) pdm 09 Virus of the H 275 Y Oseltamivir-Resistant Neuraminidase Mutations on Viral Fitness Impact of Potential Permissive , 2014 .
[46] P. Ward,et al. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1–5 years , 2003, European Journal of Clinical Pharmacology.
[47] Catherine Macken,et al. Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use , 2006, Antimicrobial Agents and Chemotherapy.
[48] Larisa V. Gubareva,et al. Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008 , 2008, Antimicrobial Agents and Chemotherapy.
[49] F Y Aoki,et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. , 2003, The Journal of antimicrobial chemotherapy.
[50] Alicia M Fry,et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. , 2014, The Lancet. Infectious diseases.
[51] Robert Schechter,et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[52] John J. Treanor,et al. Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza , 2000 .
[53] Wilhelm Huisinga,et al. ADAPTIVE SIMULATION OF HYBRID STOCHASTIC AND DETERMINISTIC MODELS FOR BIOCHEMICAL SYSTEMS , 2005 .
[54] P. Ward,et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. , 2000, JAMA.